# FLAT Study: First Line Ablation Therapy for Treatment of Paroxysmal Atrial Fibrillation (RAAFT)

> **NCT00137540** · PHASE3 · COMPLETED · sponsor: **Biosense Webster EMEA** · enrollment: 40 (actual)

## Conditions studied

- Atrial Fibrillation

## Interventions

- **DEVICE:** RF ablation
- **DRUG:** anti-arrhythmic drug therapy

## Key facts

- **NCT ID:** NCT00137540
- **Lead sponsor:** Biosense Webster EMEA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-09
- **Primary completion:** 2007-04
- **Final completion:** 2008-07
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2025-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00137540

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00137540, "FLAT Study: First Line Ablation Therapy for Treatment of Paroxysmal Atrial Fibrillation (RAAFT)". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT00137540. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*